Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

May 22, 2022

Study Completion Date

June 15, 2022

Conditions
Postpartum HemorrhageUterine Atony
Interventions
DRUG

15-methyl prostaglandin F2α

"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the carboprost study group will receive an intramuscular dose of 0.25mg (1mL) carboprost. If another second-line uterotonic is requested, the patients will receive 0.2mg (1mL) intramuscular methylergonovine."

DRUG

Methylergonovine Maleate

"Participants will receive standard intraoperative care including an infusion of oxytocin immediately postpartum. If a second-line uterotonic is requested, patients randomized to the methergine study group will receive an intramuscular dose of 0.2mg (1mL) methylergonovine. If another second-line uterotonic is requested, the patients will receive 0.25mg (1mL) intramuscular carboprost."

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Northwestern Memorial Hospital

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT03584854 - Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial | Biotech Hunter | Biotech Hunter